SCHEMBL5523345

SCHEMBL5523345

N#CCNC(=O)C(CC1CCCCC1)C(=O)Nc1ccc(Oc2ccccc2)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPY5R Q15761 1/20 0.60
CTSS P25774 4/20 0.53
CTSL P07711 3/20 0.53
CTSK P43235 3/20 0.53
CTSB P07858 1/20 0.53
MAPT P10636 5/20 0.51
SMN1; SMN2 Q16637 3/20 0.51
ALOX12 P18054 3/20 0.51
HTT P42858 3/20 0.51
ALDH1A1 P00352 3/20 0.51
EPHX1 P07099 1/20 0.48
FNTA P49354 1/20 0.46
FNTB P49356 1/20 0.46
KLK7 P49862 2/20 0.44
MEN1 O00255 1/20 0.44
HPGD P15428 1/20 0.44
KMT2A Q03164 1/20 0.44
LMNA P02545 3/20 0.43
METAP2 P50579 1/20 0.43
METAP1 P53582 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5524199 0.91 CTSS (0.50) NPY5RCTSSCTSLCTSKCTSB
SCHEMBL5526343 0.90 CTSK (0.60) NPY5RCTSSCTSLCTSKCTSB
SCHEMBL5532544 0.87 NPY5R (0.66) NPY5RCTSSCTSLMAPTSMN1; SMN2
SCHEMBL5530579 0.83 CTSL (0.52) NPY5RCTSSCTSLCTSKCTSB
SCHEMBL5520618 0.79 FPR2 (0.53) CTSSCTSLCTSKCTSBSMN1; SMN2
SCHEMBL5526359 0.79 CTSK (0.60) CTSSCTSLCTSKCTSBMETAP2
SCHEMBL5520634 0.79 CTSK (0.60) CTSSCTSLCTSKCTSBEPHX1
SCHEMBL5524207 0.79 KMT2A (0.50) CTSSCTSLCTSKCTSBMAPT
SCHEMBL5526426 0.78 CTSK (0.53) CTSSCTSLCTSKCTSBMAPT
SCHEMBL5532311 0.78 CTSS (0.64) NPY5RCTSSCTSLCTSKCTSB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040147503-A1 Antiarthritic agents; muscular dystrophy; antiinflammatory agents; antitumor agents; glomerulonephritis AXYS PHARMACEUTICALS, INC. 2004-07-29 US claimed
US-20070232654-A1 Novel Compounds and Compositions as Cathepsin Inhibitors AXYS PHARMACEUTICALS, INC. (US) 2007-10-04 US disclosed
US-20040147503-A1 Antiarthritic agents; muscular dystrophy; antiinflammatory agents; antitumor agents; glomerulonephritis AXYS PHARMACEUTICALS, INC. 2004-07-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232654-A1 Novel Compounds and Compositions as Cathepsin Inhibitors CTSS, CTSB, CTSE NPY5R 3955/4885CTSS 1/4885CTSL 11/4885
US-20040147503-A1 Antiarthritic agents; muscular dystrophy; antiinflammatory agents; antitumor agents; glomerulonephritis CAPNS1, CTSS, CTSV NPY5R 4647/4885CTSS 2/4885CTSL 19/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.